Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Catheter Ablation | 47 | 2023 | 2758 | 4.780 |
Why?
|
Portasystemic Shunt, Transjugular Intrahepatic | 8 | 2023 | 94 | 4.210 |
Why?
|
Liver Neoplasms | 23 | 2024 | 4319 | 2.720 |
Why?
|
Radiography, Interventional | 11 | 2023 | 1114 | 2.720 |
Why?
|
Radiology, Interventional | 11 | 2024 | 475 | 2.620 |
Why?
|
Mammary Neoplasms, Experimental | 17 | 2018 | 507 | 2.600 |
Why?
|
Ablation Techniques | 9 | 2021 | 248 | 2.370 |
Why?
|
Cryosurgery | 5 | 2024 | 475 | 2.330 |
Why?
|
Carcinoma, Hepatocellular | 17 | 2024 | 2299 | 2.210 |
Why?
|
Doxorubicin | 18 | 2016 | 2209 | 2.100 |
Why?
|
Chemoembolization, Therapeutic | 6 | 2023 | 127 | 1.950 |
Why?
|
Embolization, Therapeutic | 6 | 2021 | 1413 | 1.740 |
Why?
|
Antibiotics, Antineoplastic | 6 | 2016 | 675 | 1.650 |
Why?
|
Bile Duct Neoplasms | 4 | 2021 | 602 | 1.490 |
Why?
|
Hepatic Encephalopathy | 2 | 2022 | 144 | 1.440 |
Why?
|
Portal Vein | 6 | 2023 | 429 | 1.400 |
Why?
|
Rats, Inbred F344 | 20 | 2024 | 825 | 1.390 |
Why?
|
Venous Thrombosis | 6 | 2023 | 1299 | 1.380 |
Why?
|
Liver | 20 | 2024 | 7509 | 1.370 |
Why?
|
Esophageal and Gastric Varices | 3 | 2023 | 208 | 1.360 |
Why?
|
Yttrium Radioisotopes | 3 | 2024 | 107 | 1.210 |
Why?
|
End Stage Liver Disease | 2 | 2022 | 353 | 1.080 |
Why?
|
Catheterization, Peripheral | 2 | 2020 | 345 | 1.070 |
Why?
|
Hyperthermia, Induced | 8 | 2016 | 417 | 1.070 |
Why?
|
Microspheres | 3 | 2024 | 787 | 1.030 |
Why?
|
Liver Transplantation | 4 | 2023 | 2325 | 1.030 |
Why?
|
Liver Neoplasms, Experimental | 5 | 2019 | 190 | 0.980 |
Why?
|
Liposomes | 13 | 2023 | 777 | 0.970 |
Why?
|
Cholangiocarcinoma | 2 | 2021 | 550 | 0.960 |
Why?
|
Hepatectomy | 2 | 2019 | 559 | 0.920 |
Why?
|
Neoplasms, Multiple Primary | 2 | 2023 | 586 | 0.860 |
Why?
|
Evoked Potentials, Somatosensory | 1 | 2024 | 246 | 0.830 |
Why?
|
Surgery, Computer-Assisted | 5 | 2014 | 1008 | 0.820 |
Why?
|
Quercetin | 4 | 2016 | 97 | 0.750 |
Why?
|
Ultrasonography, Interventional | 7 | 2024 | 1502 | 0.750 |
Why?
|
Chemotherapy, Adjuvant | 13 | 2017 | 3529 | 0.750 |
Why?
|
Evoked Potentials, Motor | 1 | 2024 | 461 | 0.750 |
Why?
|
Splenic Artery | 1 | 2021 | 57 | 0.730 |
Why?
|
Transurethral Resection of Prostate | 1 | 2021 | 85 | 0.720 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2023 | 886 | 0.700 |
Why?
|
Patient Readmission | 3 | 2020 | 3323 | 0.700 |
Why?
|
Hand | 3 | 2024 | 903 | 0.690 |
Why?
|
Electromagnetic Phenomena | 1 | 2020 | 161 | 0.680 |
Why?
|
Neoplasms | 14 | 2021 | 22072 | 0.680 |
Why?
|
Venereal Tumors, Veterinary | 3 | 2004 | 8 | 0.670 |
Why?
|
Splenic Vein | 1 | 2019 | 30 | 0.670 |
Why?
|
Hepatic Artery | 2 | 2018 | 230 | 0.670 |
Why?
|
Pericardiectomy | 1 | 2019 | 46 | 0.660 |
Why?
|
Radial Artery | 1 | 2020 | 196 | 0.650 |
Why?
|
Cholangitis, Sclerosing | 1 | 2021 | 177 | 0.650 |
Why?
|
Microwaves | 2 | 2016 | 185 | 0.610 |
Why?
|
Health Literacy | 1 | 2023 | 440 | 0.590 |
Why?
|
Motor Skills | 1 | 2020 | 520 | 0.580 |
Why?
|
Drainage | 3 | 2022 | 1161 | 0.580 |
Why?
|
After-Hours Care | 1 | 2018 | 102 | 0.580 |
Why?
|
Adenocarcinoma | 9 | 2017 | 6315 | 0.580 |
Why?
|
Common Bile Duct Diseases | 1 | 2017 | 36 | 0.570 |
Why?
|
Heat-Shock Proteins | 4 | 2018 | 795 | 0.570 |
Why?
|
Cholestasis, Extrahepatic | 1 | 2017 | 51 | 0.570 |
Why?
|
Catheters | 2 | 2022 | 425 | 0.570 |
Why?
|
Pericardial Effusion | 1 | 2019 | 247 | 0.570 |
Why?
|
Prostatic Hyperplasia | 1 | 2021 | 530 | 0.560 |
Why?
|
Terminology as Topic | 2 | 2014 | 1535 | 0.560 |
Why?
|
HSP70 Heat-Shock Proteins | 3 | 2016 | 397 | 0.560 |
Why?
|
STAT3 Transcription Factor | 2 | 2019 | 877 | 0.550 |
Why?
|
Benchmarking | 1 | 2023 | 1044 | 0.550 |
Why?
|
Foot Diseases | 1 | 2017 | 147 | 0.540 |
Why?
|
Nickel | 1 | 2017 | 128 | 0.540 |
Why?
|
Neoplasm Seeding | 1 | 2016 | 84 | 0.530 |
Why?
|
Ampulla of Vater | 1 | 2017 | 149 | 0.530 |
Why?
|
Fibroma | 1 | 2017 | 190 | 0.520 |
Why?
|
Nanoparticles | 3 | 2016 | 1943 | 0.510 |
Why?
|
Retrospective Studies | 42 | 2024 | 80372 | 0.510 |
Why?
|
Treatment Outcome | 31 | 2024 | 65017 | 0.490 |
Why?
|
Graft Occlusion, Vascular | 1 | 2018 | 560 | 0.490 |
Why?
|
Rats | 22 | 2024 | 23711 | 0.490 |
Why?
|
Gastrointestinal Hemorrhage | 3 | 2023 | 1131 | 0.480 |
Why?
|
Sarcoma, Experimental | 2 | 2005 | 117 | 0.480 |
Why?
|
Angioplasty, Balloon | 1 | 2018 | 597 | 0.470 |
Why?
|
Clinical Competence | 6 | 2024 | 4783 | 0.470 |
Why?
|
Electric Conductivity | 6 | 2013 | 410 | 0.460 |
Why?
|
Cyclooxygenase 2 Inhibitors | 1 | 2016 | 321 | 0.460 |
Why?
|
Kidney Neoplasms | 5 | 2019 | 4312 | 0.460 |
Why?
|
Hepatocyte Growth Factor | 4 | 2022 | 267 | 0.460 |
Why?
|
Telemedicine | 2 | 2022 | 3018 | 0.460 |
Why?
|
Angioplasty | 1 | 2016 | 361 | 0.440 |
Why?
|
Postoperative Complications | 5 | 2021 | 15697 | 0.440 |
Why?
|
Device Removal | 2 | 2023 | 636 | 0.430 |
Why?
|
Microvessels | 2 | 2017 | 572 | 0.430 |
Why?
|
Sulfones | 1 | 2015 | 447 | 0.420 |
Why?
|
Electroporation | 4 | 2016 | 255 | 0.420 |
Why?
|
Humans | 93 | 2024 | 760621 | 0.410 |
Why?
|
Liver Diseases | 1 | 2021 | 1302 | 0.410 |
Why?
|
Pneumothorax | 3 | 2021 | 379 | 0.400 |
Why?
|
Middle Aged | 44 | 2024 | 220352 | 0.390 |
Why?
|
Feasibility Studies | 5 | 2023 | 5201 | 0.390 |
Why?
|
Combined Modality Therapy | 16 | 2018 | 8552 | 0.390 |
Why?
|
Female | 67 | 2024 | 391270 | 0.380 |
Why?
|
Male | 53 | 2024 | 359744 | 0.380 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2014 | 621 | 0.360 |
Why?
|
Micelles | 3 | 2016 | 192 | 0.360 |
Why?
|
Boronic Acids | 1 | 2014 | 914 | 0.350 |
Why?
|
Necrosis | 7 | 2022 | 1612 | 0.350 |
Why?
|
Thermal Conductivity | 2 | 2008 | 16 | 0.340 |
Why?
|
Thrombolytic Therapy | 1 | 2019 | 2108 | 0.340 |
Why?
|
Animals | 48 | 2024 | 167963 | 0.340 |
Why?
|
Neoplasm Transplantation | 7 | 2017 | 2014 | 0.330 |
Why?
|
Up-Regulation | 2 | 2017 | 4122 | 0.330 |
Why?
|
Ventricular Function, Left | 1 | 2022 | 3880 | 0.320 |
Why?
|
Disease Models, Animal | 13 | 2023 | 18137 | 0.320 |
Why?
|
Varicose Veins | 2 | 2023 | 155 | 0.320 |
Why?
|
Pyrazines | 1 | 2014 | 1199 | 0.310 |
Why?
|
Liver Diseases, Parasitic | 1 | 2008 | 9 | 0.310 |
Why?
|
Physicians | 2 | 2023 | 4591 | 0.310 |
Why?
|
Thrombosis | 1 | 2022 | 3052 | 0.310 |
Why?
|
Research Design | 2 | 2014 | 6180 | 0.310 |
Why?
|
Stents | 2 | 2018 | 3314 | 0.310 |
Why?
|
Internship and Residency | 3 | 2023 | 5870 | 0.310 |
Why?
|
Patient Care Planning | 1 | 2013 | 908 | 0.300 |
Why?
|
Liver Cirrhosis | 3 | 2022 | 1931 | 0.300 |
Why?
|
Schistosomiasis | 1 | 2008 | 64 | 0.300 |
Why?
|
Antineoplastic Agents | 11 | 2015 | 13630 | 0.290 |
Why?
|
Hypersensitivity | 1 | 2017 | 1155 | 0.290 |
Why?
|
Vascular Endothelial Growth Factor A | 5 | 2022 | 3484 | 0.290 |
Why?
|
Splenic Diseases | 1 | 2008 | 90 | 0.290 |
Why?
|
Indoles | 1 | 2015 | 1829 | 0.290 |
Why?
|
Heart Failure | 2 | 2022 | 11847 | 0.280 |
Why?
|
Inflammation | 3 | 2016 | 10756 | 0.280 |
Why?
|
Tomography, Spiral Computed | 2 | 2005 | 273 | 0.270 |
Why?
|
Catheterization, Central Venous | 2 | 2024 | 526 | 0.270 |
Why?
|
Carcinoma, Renal Cell | 2 | 2019 | 3218 | 0.260 |
Why?
|
RNA, Small Interfering | 1 | 2015 | 3442 | 0.260 |
Why?
|
Soft Tissue Neoplasms | 2 | 2005 | 1152 | 0.260 |
Why?
|
Mortality | 1 | 2017 | 2916 | 0.250 |
Why?
|
Aged | 27 | 2024 | 169152 | 0.250 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2023 | 9276 | 0.250 |
Why?
|
Time Factors | 16 | 2024 | 40165 | 0.240 |
Why?
|
Saline Solution, Hypertonic | 2 | 2002 | 114 | 0.240 |
Why?
|
Splenomegaly | 1 | 2005 | 189 | 0.240 |
Why?
|
Ambulatory Care | 3 | 2022 | 2781 | 0.230 |
Why?
|
Prostate | 2 | 2023 | 1793 | 0.230 |
Why?
|
Acetic Acid | 1 | 2003 | 60 | 0.220 |
Why?
|
Tomography, X-Ray Computed | 12 | 2023 | 20509 | 0.220 |
Why?
|
Dog Diseases | 1 | 2003 | 141 | 0.210 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3085 | 0.210 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3205 | 0.200 |
Why?
|
International Normalized Ratio | 1 | 2024 | 386 | 0.200 |
Why?
|
Pelvis | 2 | 2023 | 743 | 0.200 |
Why?
|
Phantoms, Imaging | 3 | 2024 | 2512 | 0.200 |
Why?
|
Granulocytes | 1 | 2023 | 551 | 0.190 |
Why?
|
Suction | 1 | 2022 | 263 | 0.190 |
Why?
|
Polyethylene Glycols | 4 | 2016 | 1189 | 0.190 |
Why?
|
Hemostatic Techniques | 1 | 2002 | 114 | 0.190 |
Why?
|
Kidney | 5 | 2015 | 7064 | 0.190 |
Why?
|
Thrombectomy | 2 | 2023 | 708 | 0.180 |
Why?
|
Vena Cava Filters | 1 | 2023 | 261 | 0.180 |
Why?
|
Myofibroblasts | 1 | 2022 | 207 | 0.180 |
Why?
|
Prostatic Neoplasms | 1 | 2023 | 11345 | 0.180 |
Why?
|
Tonsillectomy | 2 | 2000 | 268 | 0.180 |
Why?
|
Subcutaneous Tissue | 2 | 2015 | 132 | 0.180 |
Why?
|
Lymph Nodes | 3 | 2024 | 3486 | 0.170 |
Why?
|
Pandemics | 1 | 2020 | 8624 | 0.170 |
Why?
|
Bile Ducts, Intrahepatic | 1 | 2021 | 296 | 0.170 |
Why?
|
Electrocoagulation | 1 | 2000 | 152 | 0.170 |
Why?
|
Patient Satisfaction | 3 | 2023 | 3448 | 0.170 |
Why?
|
Gelatin Sponge, Absorbable | 1 | 2019 | 55 | 0.170 |
Why?
|
Adult | 23 | 2024 | 219994 | 0.170 |
Why?
|
Breast Neoplasms | 3 | 2023 | 21025 | 0.170 |
Why?
|
Punctures | 1 | 2020 | 370 | 0.160 |
Why?
|
Lymphatic Vessels | 1 | 2023 | 358 | 0.160 |
Why?
|
Mice, Inbred C57BL | 7 | 2023 | 22023 | 0.160 |
Why?
|
Cone-Beam Computed Tomography | 1 | 2023 | 471 | 0.160 |
Why?
|
Uterine Artery Embolization | 1 | 2019 | 59 | 0.160 |
Why?
|
Ascites | 2 | 2023 | 338 | 0.160 |
Why?
|
Living Donors | 1 | 2023 | 636 | 0.160 |
Why?
|
Peer Review, Health Care | 1 | 2019 | 73 | 0.160 |
Why?
|
Risk Factors | 12 | 2024 | 74359 | 0.160 |
Why?
|
Cholangiography | 1 | 2019 | 181 | 0.160 |
Why?
|
Dissection | 1 | 2000 | 298 | 0.160 |
Why?
|
Consensus | 3 | 2023 | 3113 | 0.150 |
Why?
|
Abscess | 1 | 2022 | 605 | 0.150 |
Why?
|
Employee Performance Appraisal | 1 | 2018 | 86 | 0.150 |
Why?
|
Aminosalicylic Acids | 1 | 2017 | 37 | 0.150 |
Why?
|
Angiography | 1 | 2023 | 1605 | 0.150 |
Why?
|
Uterine Hemorrhage | 1 | 2019 | 242 | 0.150 |
Why?
|
Hot Temperature | 5 | 2016 | 1435 | 0.150 |
Why?
|
Neoplasm Metastasis | 3 | 2017 | 4902 | 0.140 |
Why?
|
Macrophages | 3 | 2023 | 5745 | 0.140 |
Why?
|
Abdomen | 1 | 2023 | 1130 | 0.140 |
Why?
|
Angiography, Digital Subtraction | 1 | 2018 | 334 | 0.140 |
Why?
|
Intention to Treat Analysis | 1 | 2018 | 422 | 0.140 |
Why?
|
Magnetic Resonance Imaging | 7 | 2024 | 36290 | 0.140 |
Why?
|
Lymphedema | 1 | 2023 | 524 | 0.140 |
Why?
|
Benzenesulfonates | 1 | 2017 | 165 | 0.140 |
Why?
|
Patch Tests | 1 | 2017 | 57 | 0.140 |
Why?
|
Length of Stay | 4 | 2018 | 6479 | 0.140 |
Why?
|
Neoplasms, Connective Tissue | 1 | 2016 | 36 | 0.140 |
Why?
|
Professional Practice | 1 | 2018 | 313 | 0.140 |
Why?
|
Radiation Dosage | 2 | 2021 | 1958 | 0.140 |
Why?
|
Forkhead Transcription Factors | 1 | 2023 | 1612 | 0.130 |
Why?
|
Arteries | 1 | 2021 | 1126 | 0.130 |
Why?
|
Colorectal Neoplasms | 4 | 2023 | 6853 | 0.130 |
Why?
|
Societies, Medical | 3 | 2023 | 3905 | 0.130 |
Why?
|
Equipment Failure Analysis | 2 | 2016 | 848 | 0.130 |
Why?
|
Interleukin-6 | 2 | 2016 | 3215 | 0.130 |
Why?
|
Postpartum Hemorrhage | 1 | 2019 | 265 | 0.130 |
Why?
|
Lung Neoplasms | 4 | 2023 | 13262 | 0.130 |
Why?
|
Vascular Patency | 1 | 2018 | 901 | 0.130 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2014 | 3584 | 0.130 |
Why?
|
Dogs | 4 | 2004 | 3841 | 0.120 |
Why?
|
Checklist | 1 | 2022 | 827 | 0.120 |
Why?
|
Constriction, Pathologic | 1 | 2018 | 1098 | 0.120 |
Why?
|
Adrenal Cortex Neoplasms | 1 | 2016 | 161 | 0.120 |
Why?
|
Radiology Department, Hospital | 1 | 2018 | 405 | 0.120 |
Why?
|
Fatal Outcome | 1 | 2019 | 1832 | 0.120 |
Why?
|
Outpatients | 1 | 2022 | 1607 | 0.120 |
Why?
|
Syndrome | 1 | 2021 | 3280 | 0.120 |
Why?
|
Teaching Rounds | 1 | 2019 | 275 | 0.120 |
Why?
|
Vinblastine | 1 | 2016 | 487 | 0.120 |
Why?
|
Hypertrophy | 1 | 2016 | 555 | 0.120 |
Why?
|
Cholestasis | 1 | 2017 | 377 | 0.120 |
Why?
|
Radio Waves | 1 | 2015 | 250 | 0.120 |
Why?
|
Adrenalectomy | 1 | 2016 | 348 | 0.120 |
Why?
|
Ki-67 Antigen | 1 | 2016 | 631 | 0.110 |
Why?
|
Analgesia, Epidural | 1 | 2017 | 330 | 0.110 |
Why?
|
Hospital Mortality | 2 | 2018 | 5425 | 0.110 |
Why?
|
Severity of Illness Index | 2 | 2022 | 15840 | 0.110 |
Why?
|
Prostate-Specific Antigen | 1 | 2023 | 2529 | 0.110 |
Why?
|
Foot | 1 | 2017 | 573 | 0.110 |
Why?
|
Models, Anatomic | 1 | 2017 | 682 | 0.110 |
Why?
|
Radiology Information Systems | 1 | 2018 | 528 | 0.110 |
Why?
|
Oncogene Proteins | 1 | 2017 | 719 | 0.110 |
Why?
|
Random Allocation | 2 | 2016 | 2394 | 0.110 |
Why?
|
Fluoroscopy | 1 | 2017 | 948 | 0.110 |
Why?
|
Patient Education as Topic | 1 | 2023 | 2315 | 0.110 |
Why?
|
Hyperaldosteronism | 1 | 2016 | 244 | 0.110 |
Why?
|
Equipment Design | 4 | 2016 | 3520 | 0.110 |
Why?
|
Pancreaticoduodenectomy | 1 | 2016 | 508 | 0.100 |
Why?
|
Thoracic Vertebrae | 1 | 2017 | 597 | 0.100 |
Why?
|
Postoperative Hemorrhage | 1 | 2016 | 422 | 0.100 |
Why?
|
Cell Proliferation | 3 | 2022 | 10446 | 0.100 |
Why?
|
Dendritic Cells | 1 | 2023 | 2725 | 0.100 |
Why?
|
Predictive Value of Tests | 3 | 2024 | 15289 | 0.100 |
Why?
|
Models, Theoretical | 3 | 2019 | 3562 | 0.100 |
Why?
|
Mice | 8 | 2023 | 81208 | 0.100 |
Why?
|
Prospective Studies | 6 | 2021 | 54303 | 0.100 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2016 | 626 | 0.100 |
Why?
|
Echocardiography | 2 | 2022 | 4981 | 0.100 |
Why?
|
Electrodes | 3 | 2012 | 614 | 0.100 |
Why?
|
Documentation | 1 | 2018 | 893 | 0.100 |
Why?
|
Aldosterone | 1 | 2016 | 868 | 0.090 |
Why?
|
Sarcoma | 1 | 2002 | 1786 | 0.090 |
Why?
|
Computer Simulation | 4 | 2008 | 6218 | 0.090 |
Why?
|
Lung | 4 | 2023 | 9994 | 0.090 |
Why?
|
Aged, 80 and over | 10 | 2024 | 58995 | 0.090 |
Why?
|
Tumor Burden | 1 | 2016 | 1895 | 0.090 |
Why?
|
Neoadjuvant Therapy | 1 | 2021 | 2821 | 0.090 |
Why?
|
Down-Regulation | 1 | 2017 | 2913 | 0.090 |
Why?
|
Particle Size | 1 | 2014 | 1644 | 0.090 |
Why?
|
Muscle, Skeletal | 1 | 2005 | 4925 | 0.090 |
Why?
|
Ultrasonography | 1 | 2023 | 5961 | 0.090 |
Why?
|
Medical History Taking | 1 | 2013 | 773 | 0.090 |
Why?
|
Cell Line, Tumor | 3 | 2016 | 16939 | 0.080 |
Why?
|
Learning | 1 | 2019 | 1739 | 0.080 |
Why?
|
Software | 1 | 2023 | 4419 | 0.080 |
Why?
|
Artificial Intelligence | 1 | 2023 | 2557 | 0.080 |
Why?
|
Young Adult | 5 | 2022 | 58741 | 0.080 |
Why?
|
Swine | 7 | 2016 | 5899 | 0.080 |
Why?
|
Boston | 2 | 2019 | 9280 | 0.080 |
Why?
|
Chi-Square Distribution | 3 | 2016 | 3465 | 0.080 |
Why?
|
Pulmonary Blastoma | 1 | 2008 | 41 | 0.080 |
Why?
|
Pilot Projects | 2 | 2020 | 8555 | 0.080 |
Why?
|
Students, Medical | 1 | 2021 | 1927 | 0.080 |
Why?
|
Hepatocytes | 1 | 2015 | 1229 | 0.080 |
Why?
|
Reoperation | 1 | 2018 | 4291 | 0.080 |
Why?
|
Algorithms | 3 | 2023 | 13981 | 0.080 |
Why?
|
Reproducibility of Results | 2 | 2023 | 20080 | 0.080 |
Why?
|
Stroke Volume | 1 | 2022 | 5523 | 0.070 |
Why?
|
Graft Survival | 1 | 2018 | 3794 | 0.070 |
Why?
|
Recurrence | 1 | 2020 | 8482 | 0.070 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2017 | 2828 | 0.070 |
Why?
|
Preoperative Care | 2 | 2013 | 2256 | 0.070 |
Why?
|
Physical Examination | 1 | 2013 | 1244 | 0.070 |
Why?
|
Injections, Intravenous | 3 | 2004 | 1385 | 0.070 |
Why?
|
Pain Measurement | 1 | 2017 | 3528 | 0.070 |
Why?
|
Medical Oncology | 1 | 2019 | 2313 | 0.070 |
Why?
|
MicroRNAs | 1 | 2023 | 3790 | 0.070 |
Why?
|
Perfusion | 2 | 2008 | 1376 | 0.070 |
Why?
|
Immunohistochemistry | 3 | 2015 | 11071 | 0.070 |
Why?
|
Ethanol | 2 | 2003 | 1323 | 0.070 |
Why?
|
Mice, Nude | 1 | 2013 | 3607 | 0.070 |
Why?
|
Activities of Daily Living | 1 | 2016 | 2417 | 0.070 |
Why?
|
Mentors | 2 | 2022 | 661 | 0.070 |
Why?
|
Phosphorylation | 1 | 2017 | 8313 | 0.070 |
Why?
|
Spinal Cord Injuries | 1 | 2014 | 924 | 0.070 |
Why?
|
Adenoma | 1 | 2016 | 2148 | 0.060 |
Why?
|
Quality Improvement | 2 | 2018 | 3836 | 0.060 |
Why?
|
Neovascularization, Pathologic | 1 | 2015 | 2640 | 0.060 |
Why?
|
Gene Expression | 1 | 2017 | 7588 | 0.060 |
Why?
|
Lumbar Vertebrae | 1 | 2014 | 1868 | 0.060 |
Why?
|
Injections, Intralesional | 1 | 2005 | 278 | 0.060 |
Why?
|
Attitude of Health Personnel | 1 | 2018 | 3865 | 0.060 |
Why?
|
Extracellular Fluid | 1 | 2005 | 165 | 0.060 |
Why?
|
Regression Analysis | 3 | 2016 | 6360 | 0.060 |
Why?
|
Bronchography | 1 | 2003 | 76 | 0.060 |
Why?
|
Immunotherapy | 1 | 2019 | 4642 | 0.050 |
Why?
|
Health Care Surveys | 2 | 2023 | 2435 | 0.050 |
Why?
|
Pleural Neoplasms | 1 | 2008 | 609 | 0.050 |
Why?
|
Lactates | 1 | 2024 | 404 | 0.050 |
Why?
|
Pyruvic Acid | 1 | 2024 | 195 | 0.050 |
Why?
|
Lymphography | 1 | 2023 | 188 | 0.050 |
Why?
|
Paclitaxel | 1 | 2010 | 1736 | 0.050 |
Why?
|
Prognosis | 2 | 2022 | 29658 | 0.050 |
Why?
|
Phosphofructokinase-2 | 1 | 2022 | 32 | 0.050 |
Why?
|
Diagnostic Imaging | 1 | 2017 | 3527 | 0.050 |
Why?
|
Systems Analysis | 1 | 2023 | 169 | 0.050 |
Why?
|
alpha-Fetoproteins | 1 | 2023 | 222 | 0.050 |
Why?
|
Radiography | 2 | 2012 | 6965 | 0.050 |
Why?
|
Bilirubin | 1 | 2024 | 438 | 0.050 |
Why?
|
Lymphatic System | 1 | 2023 | 254 | 0.050 |
Why?
|
Observer Variation | 1 | 2008 | 2601 | 0.050 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2005 | 640 | 0.050 |
Why?
|
Rabbits | 2 | 2005 | 4773 | 0.050 |
Why?
|
Sodium Chloride | 1 | 2004 | 591 | 0.050 |
Why?
|
Follow-Up Studies | 3 | 2018 | 39261 | 0.050 |
Why?
|
Patient Selection | 1 | 2013 | 4283 | 0.050 |
Why?
|
Spectrometry, Fluorescence | 1 | 2003 | 687 | 0.050 |
Why?
|
Tissue Distribution | 1 | 2005 | 2262 | 0.050 |
Why?
|
Drug Synergism | 1 | 2005 | 1754 | 0.050 |
Why?
|
Cyclosporine | 1 | 2003 | 777 | 0.050 |
Why?
|
Absorptiometry, Photon | 1 | 2007 | 1736 | 0.050 |
Why?
|
Ultrasonic Therapy | 1 | 2002 | 215 | 0.050 |
Why?
|
Referral and Consultation | 1 | 2013 | 3598 | 0.050 |
Why?
|
Temperature | 2 | 2006 | 2221 | 0.040 |
Why?
|
Vena Cava, Inferior | 1 | 2023 | 458 | 0.040 |
Why?
|
Nanostructures | 1 | 2005 | 547 | 0.040 |
Why?
|
Fluorouracil | 1 | 2005 | 1631 | 0.040 |
Why?
|
Tonsillar Neoplasms | 1 | 2000 | 50 | 0.040 |
Why?
|
Hospitalization | 2 | 2017 | 10790 | 0.040 |
Why?
|
Administration, Cutaneous | 1 | 2002 | 713 | 0.040 |
Why?
|
Task Performance and Analysis | 1 | 2024 | 759 | 0.040 |
Why?
|
Anti-Infective Agents, Local | 1 | 2002 | 247 | 0.040 |
Why?
|
Palatine Tonsil | 1 | 2000 | 193 | 0.040 |
Why?
|
Hemorrhage | 2 | 2024 | 3600 | 0.040 |
Why?
|
Chest Tubes | 1 | 2020 | 152 | 0.040 |
Why?
|
Dilatation and Curettage | 1 | 2019 | 52 | 0.040 |
Why?
|
Contrast Media | 3 | 2022 | 5305 | 0.040 |
Why?
|
Cisplatin | 1 | 2005 | 1644 | 0.040 |
Why?
|
Video Recording | 1 | 2024 | 955 | 0.040 |
Why?
|
Niacinamide | 1 | 2021 | 414 | 0.040 |
Why?
|
Hemoptysis | 1 | 2020 | 152 | 0.040 |
Why?
|
Pleura | 1 | 2020 | 244 | 0.040 |
Why?
|
Joint Commission on Accreditation of Healthcare Organizations | 1 | 2018 | 92 | 0.040 |
Why?
|
Fever | 1 | 2006 | 1617 | 0.040 |
Why?
|
Glycolysis | 1 | 2022 | 828 | 0.040 |
Why?
|
Forms and Records Control | 1 | 2019 | 158 | 0.040 |
Why?
|
Multivariate Analysis | 3 | 2016 | 12159 | 0.040 |
Why?
|
Creatinine | 1 | 2024 | 1903 | 0.040 |
Why?
|
Spectroscopy, Near-Infrared | 1 | 2003 | 741 | 0.040 |
Why?
|
United States | 3 | 2023 | 72461 | 0.040 |
Why?
|
Credentialing | 1 | 2018 | 115 | 0.040 |
Why?
|
Phenylurea Compounds | 1 | 2021 | 529 | 0.040 |
Why?
|
Thorax | 1 | 2021 | 553 | 0.040 |
Why?
|
Skin Neoplasms | 1 | 2017 | 5799 | 0.040 |
Why?
|
Emergency Service, Hospital | 1 | 2017 | 7818 | 0.040 |
Why?
|
Risk Assessment | 3 | 2016 | 24123 | 0.040 |
Why?
|
Lactic Acid | 1 | 2022 | 1134 | 0.040 |
Why?
|
Needles | 1 | 2020 | 451 | 0.040 |
Why?
|
Feedback, Psychological | 1 | 2017 | 95 | 0.030 |
Why?
|
Cattle | 2 | 2016 | 3847 | 0.030 |
Why?
|
Immunity | 1 | 2022 | 998 | 0.030 |
Why?
|
Sarcoma, Yoshida | 1 | 1986 | 11 | 0.030 |
Why?
|
Clinical Coding | 1 | 2018 | 181 | 0.030 |
Why?
|
Agar | 2 | 2006 | 55 | 0.030 |
Why?
|
Polyethylene Terephthalates | 1 | 1986 | 115 | 0.030 |
Why?
|
Neuroendocrine Tumors | 1 | 2002 | 650 | 0.030 |
Why?
|
Laser Therapy | 1 | 2002 | 1089 | 0.030 |
Why?
|
Fluorescent Dyes | 1 | 2003 | 1913 | 0.030 |
Why?
|
Wounds and Injuries | 1 | 2008 | 2477 | 0.030 |
Why?
|
Biomedical Research | 1 | 2011 | 3426 | 0.030 |
Why?
|
Career Choice | 1 | 2021 | 754 | 0.030 |
Why?
|
Apoptosis | 4 | 2013 | 9501 | 0.030 |
Why?
|
Florida | 1 | 2016 | 430 | 0.030 |
Why?
|
Linear Models | 1 | 2005 | 5877 | 0.030 |
Why?
|
Calcinosis | 1 | 2003 | 1476 | 0.030 |
Why?
|
Fertility | 1 | 2019 | 773 | 0.030 |
Why?
|
Trachea | 1 | 2020 | 1082 | 0.030 |
Why?
|
Ischemia | 1 | 2023 | 1893 | 0.030 |
Why?
|
Workflow | 1 | 2019 | 852 | 0.030 |
Why?
|
Disease-Free Survival | 2 | 2016 | 6828 | 0.030 |
Why?
|
Neoplasm Staging | 2 | 2023 | 11152 | 0.030 |
Why?
|
Abortion, Induced | 1 | 2019 | 460 | 0.030 |
Why?
|
Personal Satisfaction | 1 | 2018 | 643 | 0.030 |
Why?
|
Kaplan-Meier Estimate | 2 | 2016 | 6544 | 0.030 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2000 | 1375 | 0.030 |
Why?
|
Sulfur Hexafluoride | 1 | 2012 | 26 | 0.030 |
Why?
|
Analysis of Variance | 2 | 2012 | 6238 | 0.030 |
Why?
|
Chronic Disease | 1 | 2008 | 9287 | 0.030 |
Why?
|
Triiodobenzoic Acids | 1 | 2012 | 123 | 0.030 |
Why?
|
Sensitivity and Specificity | 1 | 2008 | 14660 | 0.030 |
Why?
|
Diagnosis, Differential | 1 | 2008 | 12965 | 0.030 |
Why?
|
Adolescent | 5 | 2016 | 87810 | 0.020 |
Why?
|
Iohexol | 1 | 2012 | 204 | 0.020 |
Why?
|
Models, Biological | 1 | 2008 | 9467 | 0.020 |
Why?
|
Phthalic Acids | 1 | 1986 | 476 | 0.020 |
Why?
|
Retreatment | 1 | 2012 | 600 | 0.020 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2011 | 11712 | 0.020 |
Why?
|
Mice, Inbred BALB C | 1 | 2019 | 6216 | 0.020 |
Why?
|
Radiography, Thoracic | 1 | 2017 | 1296 | 0.020 |
Why?
|
Immunosuppressive Agents | 1 | 2003 | 4166 | 0.020 |
Why?
|
Logistic Models | 2 | 2016 | 13314 | 0.020 |
Why?
|
Deoxyguanosine | 1 | 2010 | 92 | 0.020 |
Why?
|
Health Personnel | 1 | 2023 | 3310 | 0.020 |
Why?
|
ROC Curve | 1 | 2017 | 3568 | 0.020 |
Why?
|
Aldehydes | 1 | 2010 | 170 | 0.020 |
Why?
|
Endpoint Determination | 1 | 2011 | 597 | 0.020 |
Why?
|
Phospholipids | 1 | 2012 | 789 | 0.020 |
Why?
|
Acetylcysteine | 1 | 2010 | 264 | 0.020 |
Why?
|
Thermography | 1 | 2008 | 63 | 0.020 |
Why?
|
Point-of-Care Systems | 1 | 2017 | 1204 | 0.020 |
Why?
|
Disability Evaluation | 1 | 2016 | 1826 | 0.020 |
Why?
|
Survival Rate | 2 | 2012 | 12808 | 0.020 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2005 | 8950 | 0.020 |
Why?
|
Caspase 3 | 1 | 2010 | 731 | 0.020 |
Why?
|
Biopsy, Needle | 1 | 2012 | 1630 | 0.020 |
Why?
|
Quality Indicators, Health Care | 1 | 2017 | 1824 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2010 | 1705 | 0.020 |
Why?
|
Nephrectomy | 1 | 2012 | 1016 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2002 | 8056 | 0.020 |
Why?
|
Antihypertensive Agents | 1 | 2016 | 2061 | 0.020 |
Why?
|
Computer Graphics | 1 | 2008 | 341 | 0.020 |
Why?
|
Staining and Labeling | 1 | 2010 | 1089 | 0.020 |
Why?
|
Finite Element Analysis | 1 | 2008 | 428 | 0.020 |
Why?
|
Cell Survival | 1 | 2016 | 5797 | 0.020 |
Why?
|
Tyrosine | 1 | 2010 | 1438 | 0.020 |
Why?
|
Medicare | 1 | 2023 | 6786 | 0.020 |
Why?
|
Mass Screening | 1 | 2000 | 5423 | 0.010 |
Why?
|
Adrenergic Agonists | 1 | 2004 | 58 | 0.010 |
Why?
|
Odds Ratio | 1 | 2016 | 9716 | 0.010 |
Why?
|
Halothane | 1 | 2004 | 200 | 0.010 |
Why?
|
Arsenicals | 1 | 2004 | 117 | 0.010 |
Why?
|
Physician-Patient Relations | 1 | 2017 | 3242 | 0.010 |
Why?
|
Laser-Doppler Flowmetry | 1 | 2004 | 239 | 0.010 |
Why?
|
Calcium Oxalate | 1 | 2003 | 75 | 0.010 |
Why?
|
Imaging, Three-Dimensional | 2 | 2008 | 4048 | 0.010 |
Why?
|
Survival Analysis | 1 | 2015 | 10182 | 0.010 |
Why?
|
Durapatite | 1 | 2003 | 163 | 0.010 |
Why?
|
Oxides | 1 | 2004 | 401 | 0.010 |
Why?
|
Academic Medical Centers | 1 | 2012 | 2754 | 0.010 |
Why?
|
Incidence | 1 | 2020 | 21392 | 0.010 |
Why?
|
Autoradiography | 1 | 2002 | 730 | 0.010 |
Why?
|
Surface-Active Agents | 1 | 2002 | 150 | 0.010 |
Why?
|
Cohort Studies | 2 | 2016 | 41335 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2016 | 12531 | 0.010 |
Why?
|
Pneumonectomy | 1 | 2008 | 1111 | 0.010 |
Why?
|
Tonsillitis | 1 | 2000 | 28 | 0.010 |
Why?
|
Pseudolymphoma | 1 | 2000 | 30 | 0.010 |
Why?
|
Child | 3 | 2012 | 79806 | 0.010 |
Why?
|
Databases, Factual | 1 | 2016 | 8035 | 0.010 |
Why?
|
Child, Preschool | 2 | 2000 | 42063 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2022 | 25942 | 0.010 |
Why?
|
Regional Blood Flow | 1 | 2004 | 1490 | 0.010 |
Why?
|
Epinephrine | 1 | 2004 | 791 | 0.010 |
Why?
|
DNA Damage | 1 | 2010 | 2442 | 0.010 |
Why?
|
Pakistan | 1 | 2000 | 304 | 0.010 |
Why?
|
Signal Processing, Computer-Assisted | 1 | 2007 | 1489 | 0.010 |
Why?
|
Histones | 1 | 2010 | 2583 | 0.010 |
Why?
|
Body Temperature Regulation | 1 | 2001 | 286 | 0.010 |
Why?
|
Pulmonary Embolism | 1 | 2012 | 2543 | 0.010 |
Why?
|
Anesthetics, Inhalation | 1 | 2004 | 574 | 0.010 |
Why?
|
Body Composition | 1 | 2008 | 2419 | 0.010 |
Why?
|
Oxidative Stress | 1 | 2010 | 3106 | 0.010 |
Why?
|
Radiometry | 1 | 2003 | 813 | 0.010 |
Why?
|
Pregnancy | 1 | 2019 | 29749 | 0.010 |
Why?
|
Infusions, Intravenous | 1 | 2002 | 2234 | 0.010 |
Why?
|
Hypertension | 1 | 2016 | 8594 | 0.010 |
Why?
|
Models, Animal | 1 | 2002 | 2117 | 0.010 |
Why?
|
Disease Progression | 1 | 2012 | 13502 | 0.010 |
Why?
|
Medical Records | 1 | 2000 | 1407 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2012 | 22053 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 2002 | 6131 | 0.010 |
Why?
|
Carcinoma | 1 | 2004 | 2331 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2001 | 10827 | 0.000 |
Why?
|
Cost-Benefit Analysis | 1 | 2000 | 5508 | 0.000 |
Why?
|
Genetic Predisposition to Disease | 1 | 2008 | 17790 | 0.000 |
Why?
|
Infant | 1 | 2008 | 36060 | 0.000 |
Why?
|